STOCK TITAN

Trinity Biotech Plc - TRIB STOCK NEWS

Welcome to our dedicated page for Trinity Biotech Plc news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech Plc stock.

Trinity Biotech PLC (TRIB) specializes in innovative diagnostic solutions for global healthcare challenges, from infectious disease detection to diabetes management technologies. This news hub provides investors and healthcare professionals with essential updates on the company's strategic developments, regulatory milestones, and market positioning.

Access authoritative reporting on earnings announcements, product innovations, and strategic partnerships that shape Trinity Biotech's role in clinical diagnostics. Our curated collection includes press releases detailing advancements in continuous glucose monitoring systems, maternal health screenings, and bioinformatics-powered diagnostic platforms.

Stay informed about TRIB's acquisition strategies enhancing its technological capabilities and global distribution network expansion. All content is verified for accuracy and relevance to support informed decision-making and industry analysis.

Bookmark this page for streamlined access to Trinity Biotech's latest developments in medical diagnostics and corporate updates. Check regularly for real-time insights into how the company addresses evolving healthcare needs through cutting-edge biotechnology solutions.

Rhea-AI Summary

Trinity Biotech (TRIB) has received two non-compliance notices from Nasdaq regarding listing requirements. The first notice concerns the company's failure to maintain a minimum bid price of $1.00 per share for its American depositary shares (ADSs). The second notice relates to not meeting the minimum market value of publicly held shares (MVPHS) requirement of $15,000,000.

The company has until September 10, 2025 to regain compliance with both requirements. For the bid price requirement, TRIB must maintain a closing bid price above $1.00 for at least 10 consecutive business days. For the MVPHS requirement, the company must exceed $15,000,000 for a minimum of 10 consecutive business days.

If Trinity fails to meet these requirements, it may be eligible for additional grace periods or could seek transfer to the Nasdaq Capital Market. The notices do not immediately affect TRIB's listing status, and shares continue trading on the Nasdaq Global Select Market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
none
-
Rhea-AI Summary

Trinity Biotech (Nasdaq: TRIB) has appointed Barclays Capital Inc. as its exclusive financial advisor to support its strategic realignment, focusing primarily on Continuous Glucose Monitoring (CGM) technology development. This appointment marks a significant step in the company's transformation plan.

The company's decision follows substantial progress in developing its differentiated CGM technology, which promises to be more affordable, user-focused, and sustainable. CEO John Gillard highlighted strong pre-pivotal clinical trial data and market interest as key factors driving this strategic direction.

The transformation plan aims to achieve near-term profitability improvements while optimizing the company's portfolio to support CGM-related growth. Barclays will actively assess how Trinity Biotech's existing businesses can align with this new strategic focus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Trinity Biotech (TRIB) has secured an additional $4 million in debt financing from Perceptive Advisors to support two key initiatives: the continued development of its continuous glucose monitoring (CGM) technology and the company's transformation plan.

The funding follows previously announced positive results from Trinity's pre-pivotal CGM trial. The company's transformation plan aims to enhance profitability and cash-flow generation across its portfolio of operating businesses. Trinity has already implemented measures to increase operational efficiencies and continues to optimize its business portfolio and capital structure.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.91%
Tags
none
Rhea-AI Summary

Trinity Biotech (TRIB) announced significant improvements in its next-generation continuous glucose monitoring (CGM) system from its latest pre-pivotal trial. The trial, involving 30 diabetic participants over a 15-day period, demonstrated a 35% improvement in Mean Absolute Relative Difference (MARD) and over 50% improvement in Mean Absolute Difference (MAD) during the critical first-day performance compared to the previous Waveform product.

Key achievements include superior signal quality, enhanced post-insertion reliability, and a 25-30% overall improvement in MARD over earlier Waveform CGM sensors. The company's redesigned ergonomic modular CGM system focuses on affordability and sustainability with reusable and rechargeable components.

Trinity Biotech plans regulatory submissions in Europe in 2025 and FDA filing in 2026. Additional pre-pivotal clinical trials on device enhancements are scheduled to begin in Q1 2025. The global CGM market is projected to exceed $20 billion by 2029.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
none
-
Rhea-AI Summary

Trinity Biotech (TRIB) has announced significant results from its pre-pivotal trial for its next-generation continuous glucose monitoring (CGM) system. The trial, involving 30 diabetic participants over a 15-day period, demonstrated notable improvements including a 25-30% enhancement in accuracy metrics (MARD) compared to previous Waveform CGM sensors.

The company's innovative CGM features a reusable applicator and rechargeable transmitter, designed to reduce costs significantly compared to current market leaders. The system showed superior signal quality, enhanced post-insertion reliability, and industry-standard low-glucose precision.

Trinity aims to target the global CGM market, projected to exceed $20 billion by 2029. The company plans to file for EU regulatory approval in 2025 and FDA approval in 2026. Currently, the two largest CGM manufacturers serve only 10 million users out of 800 million people living with diabetes worldwide, primarily due to cost barriers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
78.95%
Tags
none
-
Rhea-AI Summary

Trinity Biotech (TRIB) has amended agreements with Perceptive Advisors, securing additional liquidity of approximately $5.5 million through cash and payment-in-kind interest. The company also extended a $5 million deferred payment for the Waveform Technologies biosensor assets to November 2025.

As part of the agreement, Trinity granted Perceptive 1.5 million additional ADS warrants and repriced existing warrants to $0.80 per ADS. The company recently received WHO approval for transferring late-stage manufacturing of TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturer, advancing its Comprehensive Transformation Plan focused on achieving long-term profitability through operational efficiency.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.75%
Tags
none
Rhea-AI Summary

Trinity Biotech (TRIB) has received early approval from the World Health Organization (WHO) to transfer the manufacturing of TrinScreen HIV and Uni-Gold HIV tests to a lower-cost offshore facility. This approval is a key milestone in the company's Comprehensive Transformation Plan, enabling the later-stage manufacturing processes of both rapid HIV tests at an outsourced provider. The company plans to begin manufacturing at the new location in Q1 2025, a move expected to improve margins and enhance shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.33%
Tags
none
-
Rhea-AI Summary

Trinity Biotech (TRIB) reported Q3 2024 total revenue of $15.2 million, up 3% year-over-year, driven by strong Point-of-Care product revenue growth of 60% Y/Y to $4.3 million. The company's operating loss improved by 51% to $2.2 million from $4.5 million in Q3 2023. TrinScreen HIV sales reached $2.4 million in Q3. The company reiterates guidance to achieve approximately $20 million of annualized run-rate EBITDASO on revenues of $75 million by Q2 2025. Trinity completed two strategic acquisitions in lab-based diagnostics and continues progress on its CGM development. Cash balance decreased to $2.8 million at quarter-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.43%
Tags
-
Rhea-AI Summary

Trinity Biotech (Nasdaq: TRIB), a commercial stage biotechnology company specializing in diabetes management solutions and human diagnostics, will announce its Q3 2024 financial results on Friday, November 15, 2024. The company will host a conference call at 10:00 AM ET. Trinity Biotech focuses on developing diagnostic systems and has recently entered the wearable biosensor industry through the acquisition of Waveform Technologies Inc.'s biosensor assets. The company sells directly in the US, Germany, France, and the UK, while maintaining distribution partnerships across 75 countries worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
Rhea-AI Summary

Trinity Biotech (Nasdaq: TRIB) has successfully regained compliance with Nasdaq's minimum market value of publicly held shares (MVPHS) requirement. The company received confirmation from Nasdaq on November 6, 2024, following a previous deficiency notice received on November 21, 2023, when its MVPHS fell below the required $15 million threshold. After presenting its compliance plan to the Nasdaq Hearings Panel on July 16, 2024, Trinity was granted an extension until October 31, 2024. The company has now met the requirement, ensuring continued listing on the Nasdaq Global Select Market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
Trinity Biotech Plc

Nasdaq:TRIB

TRIB Rankings

TRIB Stock Data

10.56M
15.17M
12.4%
14.69%
0.58%
Medical Devices
Healthcare
Link
Ireland
Bray